The objective of this study is to obtain and report outcome data for adult patients who received systemic antifungal therapy (AFT) for the treatment of invasive mucormycosis (IM) or invasive aspergillosis (IA) caused by a non-fumigatus species.
This study seeks to describe representative real-world patterns of
care for the management of invasive fungal infections (IFIs),
including invasive mold infection (IMI). Specifically, the study
goals are to examine real world patient characteristics and
treatment patterns, associated healthcare resource utilization, and
outcomes associated with use of mold-active triazoles (MATs) to
This study will be performed as a part of prospective observational American Association for the Surgery of Trauma (AAST) multi-institutional trial analyzing emergency department thoracotomies performed at trauma centers throughout the United States will be performed. After each EDT, all medical personnel involved in the resuscitation will complete a questionnaire. The primary endpoint will be occupational exposure during the thoracotomy. Secondary endpoints will include observance of universal precautions and proper reporting of occupational exposures using institutional protocols.
The purpose of this study is to develop a possible new treatment for influenza. This new treatment uses antibodies against this virus. Antibodies are natural proteins made by the body that attack influenza and other germs. We want to see if the plasma with higher levels of antibodies helps people with influenza improve more than plasma with lower levels or no antibodies. The plasma is given in addition to standard anti-influenza medications.
As people get older, the immune system can become less effective at dealing with infectious diseases. This decreased immune function can be highly variable from person to person, and at different ages in life. Many people carry a virus (called cytomegalovirus) for their whole life – this virus causes no symptoms in most people, but may influence how their immune system works as they get older. This process of “immune aging” may happen more quickly in people with HIV infection.
This study will examine immunity in a very large group of healthy individuals between the ages of 21 up to 100+ years. The goal of the study is to learn why some individuals have an increased sensitivity to new infections, such as West Nile Virus, and/or poor response to vaccinations (such as the flu vaccine). This information will be used to discover which parts of immunity may not be working properly.
The purpose of this study is to learn about lung complications in HIV patients on antiretroviral treatment for at least 3 years. This study includes a chest CT scan, lung function tests, health questionnaire, blood draw and bronchoscopy.